Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Innate Pharma SA : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
03/15/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 03/20/2019. Generally, the company reports earnings better than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have revised their EPS estimates upward.

Annual earnings per share is expected at -0.05 EUR for 2018 (- 94.4% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million €
Released
Forecast
Spread
25,1
23,3
8,1%
65,7
44,9
46%
44,0
44,0
0,15%

75,2

151
Operating income (EBITDA)
Million €
Released
Forecast
Spread
-8,12
-2,94
-176%
10,8
8,72
24%
-35,6
-5,39
-560%

-2,63

51,3
Operating profit (EBIT)
Million €
Released
Forecast
Spread
-10,8
-13,7
21%
7,57
-1,70
545%
-40,0
-19,8
-102%

-18,8

20,4
Pre-Tax Profit (EBT)
Million €
Released
Forecast
Spread
-6,71
-1,65
-306%
12,9
3,38
283%
-48,0
-22,1
-117%

-15,5

-7,60
Net income
Million €
Released
Forecast
Spread
-6,71
-10,4
35%
12,6
1,48
754%
-48,4
-23,3
-108%

-3,10

12,3
EPS
 €
Released
Forecast
Spread
-0,13
0,04
-454%
0,23
0,06
283%
-0,89
-0,42
-112%

-0,05

-0,02
Announcement Date02/18/201603/07/201703/08/2018
Stocks mentioned in the article
ChangeLast1st jan.
INNATE PHARMA 2.75% 4.778 Real-time Quote.-19.83%
THOMSON REUTERS CORPORATION 0.50% 87.06 Delayed Quote.-6.74%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INNATE PHARMA
03/10INNATE PHARMA : First patient dosed in IPH5201 Phase I clinical trial in advance..
AQ
03/10INNATE PHARMA : reports full year 2019 financial results and business update
GL
03/10First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumor..
GL
03/10INNATE PHARMA : Annual results
CO
03/10INNATE PHARMA : Slide show results
CO
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/29Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
01/14INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
01/13French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitme..
GL
More news
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -16,3 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
P/E ratio 2019 -34,6x
P/E ratio 2020 -95,6x
EV / Sales2019 3,62x
EV / Sales2020 2,39x
Capitalization 377 M
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 11,92  €
Last Close Price 4,78  €
Spread / Highest target 226%
Spread / Average Target 149%
Spread / Lowest Target 88,4%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-19.83%418
LONZA GROUP11.21%29 660
IQVIA HOLDINGS INC.-30.66%20 658
CELLTRION, INC.3.08%20 147
SEATTLE GENETICS, INC.-4.37%18 823
INCYTE CORPORATION-16.34%14 949